Evidence map›Paper›PMID 39428536›Full record

Observational studyInternal medicine (Tokyo, Japan)2025

Potential Effects of Sacubitril/Valsartan on the Cardio-ankle Vascular Index in Hypertensive Patients.

Kazuhiro Shimizu, Tsuyoshi Tabata, Masahiro Iwakawa, Yuki Ikeda, Takushi Ikeda, Shoya Nonaka, Shuji Sato, Takahiro Nakagami, Hiroshi Mikamo, Toshio Kinoshita

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kazuhiro ShimizuDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Tsuyoshi TabataDepartment of Clinical Functional Physiology, Toho University Sakura Medical Center, Japan.
Masahiro IwakawaDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Yuki IkedaDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Takushi IkedaDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Shoya NonakaDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Shuji SatoDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Takahiro NakagamiDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Hiroshi MikamoDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.
Toshio KinoshitaDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Angiotensin receptor-neprilysin inhibitors (ARNIs) have been widely used as a treatment for heart failure. However, they have only been approved for the treatment of hypertension in a limited number of countries. We investigated the effect of ARNIs on arterial stiffness using the cardio-ankle vascular index (CAVI) in patients with hypertension to reveal the mechanism underlying cardiovascular interaction. Methods We investigated the utility of ARNIs in patients in whom arterial stiffness was assessed using the CAVI before and after ARNI administration. Patients In this retrospective observational study, we enrolled 50 patients with hypertension treated with ARNIs between January 2021 and 2023. Forty-eight of the 50 patients (96%) were switched from angiotensin II receptor blockers due to inadequate antihypertensive control. Results The systolic blood pressure (BP), diastolic BP, and CAVI were significantly decreased by ARNI administration [systolic BP: 145 (135, 162) to 131 (123, 143) mmHg (p=0.000); diastolic BP: 92 (78, 100) to 82 (74, 89) mmHg (p=0.000); and CAVI: 9.9 (9.1, 10.5) to 9.5 (8.8, 10.2) (p=0.005), respectively]. Conclusion Hypertension treatment with ARNIs may improve not only the blood pressure but also the CAVI, reducing the afterload on the heart.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsCardio Ankle Vascular IndexHypertensionValsartanVascular StiffnessAgedAntihypertensive AgentsBlood PressureDrug CombinationsFemaleHumansMaleMiddle AgedNeprilysinAminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug CombinationsNeprilysinsacubitril and valsartan sodium hydrate drug combinationValsartanangiotensin receptor-neprilysin inhibitorarterial stiffnesscardio-ankle vascular indexhypertension

Identifiers

PMID39428536
PMCPMC12183418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.